JP Morgan Health Conference highlights: Gene sequencing and Chip solutions big

Monday to Friday is JP Morgan 33rd Health Investment and Financing Conference, every year at the convention, each health bio-company will come up with their own heavyweight cards, or performance revenue, or new product launch to attract attention, investors favor.

At the opening meeting, Daniel Illumina, a gene sequencing and chip solution, announced his own performance--an annual growth of 31%. and released 4 new sequencing products: HiSeq X hep System, HiSeq3000, HiSeq4000, Nexseq550.

According to Illumina's official introduction, HiSeq x hep is lower than the HiSeq X ten, a lower-cost business suit that focuses on sequencing large-scale human genome. The HISEQX hep System consists of 5 HiSeq x, which can be upgraded to HiSeq X ten to achieve a full genome sequencing of 1000 million people. Each unit reaches $120 trillion, meaning that each genome sequencing cost is raised to 1400 dollars.

HISEQ 3000 and HISEQ 4000 use an innovative, orderly flow trough technology based on reliable HISEQ 2500, which provides unmatched sequencing speed and performance. The HISEQ 4000 system is equipped with 2 flow slots that provide the highest sequencing flux and lowest sequencing cost for a wide variety of applications. The HiSeq3000 system with 1 mobile slots has the same performance.

NEXTSEQ550 on the basis of the original high throughput sequencing platform NextSeq500, the chip scanning function is added. The system is a new bridge for users to transform to sequencing technology platform based on chip application. In clinical markets, the use of the same system can complement different applications, such as cytogenetic analysis and screening of preimplantation genetic diseases.

In addition to introducing new products, Illumina also announced the introduction of clinical retail operations such as NIPT and cancer detection, focusing on platform building and partnering with various service companies.